Please login to the form below

niraparib

This page shows the latest niraparib news and features for those working in and with pharma, biotech and healthcare.

FDA accepts review to broaden GSK’s Zejula label

GSK is seeking approval for Zejula (niraparib) as a first-line maintenance treatment for women with advanced ovarian cancer who responded to platinum-based chemotherapy, regardless of biomarker status.

Latest news

GSK pays $50m upfront to tap Immatics’ cell therapy platform

GSK took full ownership of the therapy in 2018. GSK’s push into cancer has also included its $5.1bn acquisition of Tesaro, which brought in PARP inhibitor Zejula (niraparib).
Clovis leapfrogs PARP rivals, filing Rubraca for prostate cancer

The filing means that Rubraca has beaten rivals such as AstraZeneca/Merck &Co’s market-leading Lynparza (olaparib), GlaxoSmithKline/Janssen’s Zejula (niraparib) and Pfizer’s new entrant Talzenna (talazoparib) to
FDA starts speedy review of Lynparza plus Avastin in ovarian cancer

If the FDA backs the new indication it will help AZ and Merck to maintain their lead over newer rivals in the PARP inhibitor class, including GlaxoSmithKline’s Zejula (niraparib), Clovis
GSK, Pfizer and Sanofi among drugmakers planning price hikes in US

GSK will also increase prices on around 30 of its drugs, including its Ellipta inhaler, its cancer drug Zejula (niraparib) and HIV products from its ViiV division.
AZ, Merck win FDA approval for Lynparza in pancreatic cancer

The approval will help AZ and Merck to maintain a lead over newer rivals in the class, including GlaxoSmithKline’s Zejula (niraparib) and Clovis Oncology’s Rubraca (rucaparib).

More from news
Approximately 4 fully matching, plus 39 partially matching documents found.

Latest Intelligence

Deal Watch April 2016

Licensing one indication for a new product is unusual not least of all because of potential pricing issues if niraparib is launched by different companies at different prices. ... 500. Tesaro (US). Janssen (US). License and collaboration. Niraparib PARP

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

No surprises: results from the ENGOT-OV16/NOVA trial of niraparib in ovarian cancer

The ENGOT-OV16/NOVA trial of niraparib was a randomized, double-blinded placebo study with women with relapsed platinum-sensitive high-grade ovarian cancer. ... The ENGOT-OV16/NOVA trial of niraparib was a randomized, double-blinded placebo study

More from PMHub
Approximately 1 fully matching, plus 0 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company

Envision Pharma Group

We are a global leader in the medical affairs space. Our purpose-built software and scientific solutions make us a unique...

Latest intelligence

Working together against COVID-19: Analysing social media conversations to see what HCPs are saying online about the global pandemic...
Vicky Bramham, Managing Director at OPEN Health PR shares tips on media relations during COVID-19: Vicky speaks with freelance health journalist Jacqui Thornton who gives her expert view on how best to approach media relations during this unprecedented time....
Are biobetters a market access opportunity?: Biobetters are biologics that have been improved compared to the marketed originator, for example in efficacy, safety, tolerability or dosing regimen....